IRVING, Texas, Nov. 5 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today said the upcoming presentation on DelSite Biotechnologies, Inc., its wholly-owned subsidiary, will be webcast live from the Kennedy I Room at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at New York City’s Palace Hotel on Wednesday, November 7th, at 2:00 pm Eastern Time.
The presentation will cover DelSite’s three key platform technologies in the areas of drug delivery and vaccine adjuvants. The Company will also provide an update on the development status of DelSite’s lead product candidate. To access the webcast, please log on to the following website: http://www.wsw.com/webcast/rrshq12/carn.pk.
DelSite Biotechnologies specializes in the development of novel liquid and powder formulations for protein/peptide therapeutics and vaccines using its proprietary platform technologies. So far this year, DelSite has signed six technology rights evaluation agreements with commercial partners and institutions that are interested in its delivery technology.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington’s DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington’s technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.
About Rodman & Renshaw, LLC
Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. It also provides research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital-intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company’s management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company’s filings with the Securities & Exchange Commission.
CONTACT: Carlton E. Turner, Chief Executive Officer of Carrington
Laboratories, Inc., +1-972-518-1300
Web site: http://www.carringtonlabs.com/
http://www.wsw.com/webcast/rrshq12/carn.pk/
